China Oncology ›› 2018, Vol. 28 ›› Issue (3): 229-235.doi: 10.19401/j.cnki.1007-3639.2018.03.010

Previous Articles     Next Articles

A meta-analysis of long non-coding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma

WANG Xiuyue, ZHAO Chuan, CHEN Che, WANG Jing, HU Lidong   

  1. Department of Clinical Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, Gansu Province, China
  • Online:2018-03-30 Published:2018-04-11
  • Contact: CHEN Che E-mail: chen72123@163.com

Abstract: Background and purpose: Long non-coding RNAs (lncRNA) are outstanding as novel cancer biomarkers with great prospects. Hence, we aimed to summarize the overall diagnostic assessment of lncRNAs for hepatocellular carcinoma (HCC). Methods: A systematic search was performed in PubMed, EMbase, Cochrane Library, CBM, CNKI and Wanfang database from establishment of the database to February 2017. The quality of included studies was evaluated using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) checklist. The pooled sensitivity, specificity, positive likelihood ratio (LR) and negative LR were analyzed using random effect model. The overall test efficacy was estimated using the summary receiver operating characteristic (ROC) curve and the area under the curve (AUC). Statistical analysis was conducted using Stata 12.0 and Meta-Disc 1.4 software. Results: A total of 13 studies involving 1296 patients with hepatocellular carcinoma and 1304 healthy controls were finally included. For overall lncRNA, the pooled sensitivity, specificity, positive LR and negative LR to predict HCC patients were 83% (95%CI: 81%-85%), 82% (95%CI: 80%-84%), 5.32 (95%CI: 3.37-8.42) and 0.21 (95%CI: 0.15-50.28), respectively, corresponding to an AUC of 0.91. Conclusion: LncRNA have high diagnostic value for HCC, and their expressions can be used as auxiliary biomarkers in confirming HCC.

Key words: Long non-coding RNA, Hepatocellular carcinoma, Diagnosis, Biomarkers, Meta-analysis